rapid
theoret
technic
progress
across
biochem
biophys
field
extens
assay
technolog
develop
discoveri
effect
therapeut
compound
postgenom
era
assay
format
divid
three
main
group
silico
screen
larg
enrich
hit
rate
compar
random
screen
vitro
biochem
assay
evalu
biolog
activ
compound
target
protein
cellbas
assay
monitor
biolog
respons
compound
cell
outbreak
sar
epidem
led
worldwid
threat
human
health
novel
sever
acut
respiratori
syndrom
coronaviru
sarscov
identifi
etiolog
agent
sarscov
genomeencod
major
protein
proteas
pro
attract
target
develop
antisar
agent
due
function
import
viral
life
cycl
see
box
assay
platform
discov
effect
inhibitor
sarscov
establish
review
outlin
exist
emerg
techniqu
use
antisar
drug
discoveri
discuss
potenti
promis
advantag
limit
drug
discoveri
pipelin
develop
new
effici
strategi
distinguish
activ
inact
substanc
among
larg
number
natur
synthet
compound
critic
primari
screen
stage
subsequ
evalu
appropri
biochem
cellular
effect
compound
also
need
effect
less
expens
way
date
much
progress
made
discoveri
techniqu
aim
goal
fig
follow
section
summar
reliabl
assay
technolog
use
antisar
agent
research
silico
techniqu
clearli
becom
one
power
approach
drug
design
provid
especi
use
structur
inform
highqual
candid
follow
biolog
evalu
complementari
approach
experiment
highthroughput
screen
ht
virtual
screen
typic
silico
techniqu
use
screen
databas
compound
techniqu
involv
rapidli
screen
compound
databas
dock
activ
site
threedimension
protein
structur
dock
recognit
procedur
target
protein
compound
determin
geometr
energet
match
prerequisit
success
detail
understand
structur
properti
target
protein
criteria
determin
bind
ligand
recent
year
success
case
reveal
structurebas
virtual
screen
huge
enrich
hit
rate
compar
random
screen
emerg
reliabl
inexpens
method
identifi
lead
compound
vari
complementari
dock
algorithm
appli
improv
qualiti
score
function
decreas
rel
high
falseposit
rate
virtual
screen
virtual
screen
success
appli
discoveri
sarscov
inhibitor
basi
model
sarscov
pro
xiong
et
al
report
virtual
screen
studi
databas
proteas
inhibitor
discov
sever
avail
proteas
inhibitor
could
use
antisar
agent
research
along
releas
crystal
structur
sarscov
pro
complex
specif
inhibitor
pdb
id
box
put
antisarscov
drug
target
current
state
research
basi
extens
scientif
cooper
almost
studi
remark
achiev
made
understand
phylogenet
properti
genom
organ
sarscov
learn
detail
charact
major
protein
involv
sarscov
life
cycl
potenti
target
ration
design
antisar
drug
becom
appar
viral
enzym
essenti
viru
replic
exampl
pro
pro
rdrp
certainli
attract
candid
develop
therapeut
compound
sarscov
pro
could
success
express
e
coli
purifi
activ
form
report
research
progress
targetbas
drug
develop
mainli
focus
proteas
variou
techniqu
use
high
throughput
screen
small
molecul
librari
although
pro
also
attract
target
antivir
therapi
littl
inform
avail
proteas
date
except
previou
studi
express
protein
baculovirusinfect
insect
cell
character
primari
proteolyt
activ
vitro
correspond
research
extens
perform
recent
crystal
structur
pro
success
solv
afford
good
startpoint
futur
drug
discoveri
target
besid
pro
pro
rdrp
anoth
key
protein
sarscov
life
cycl
make
put
target
drug
recent
rdrp
express
purifi
biolog
form
e
coli
could
use
drug
screen
lack
solv
crystal
structur
rel
complic
experiment
process
determin
activ
limit
rapid
progress
drug
discoveri
target
rdrp
addit
discoveri
compound
block
viral
entri
also
effect
therapi
strategi
essenti
core
region
protein
receptorbind
domain
identifi
amino
acid
residu
wherea
screen
platform
compound
block
interact
report
yet
consid
reason
mention
manuscript
thu
mainli
focus
techniqu
use
identifi
effect
inhibitor
pro
figur
pictori
descript
multidisciplinebas
strategi
antisar
drug
discoveri
use
interdisciplinari
technolog
effici
rapid
discoveri
therapeut
compound
sarscov
multidisciplinarybas
strategi
might
employ
shown
optim
targetbas
antisar
drug
discoveri
pathway
base
structur
valid
target
protein
encod
sarscov
genom
silico
virtual
screen
small
molecul
databas
small
mol
db
reliabl
narrow
number
potenti
candid
afford
good
startpoint
follow
experiment
test
subsequ
sprbind
assay
use
determin
bind
affin
bind
kinet
candid
compound
appropri
biochem
cellular
effect
candid
evalu
vitro
biochem
vivo
cellbas
assay
identifi
primari
hit
compound
hit
obtain
use
structur
optim
go
screen
quantifi
structureact
relationship
hit
becom
lead
lead
compound
undergo
round
chemic
refin
biolog
screen
final
enter
clinic
test
make
drug
virtual
screen
studi
structurebas
antisar
drug
design
discoveri
perform
explor
avail
drug
virtual
screen
technolog
small
molecul
databas
identif
avail
potenti
inhibitor
provid
effect
strategi
acceler
sarscov
pro
inhibitor
discoveri
process
improv
success
rate
usual
vitro
biochem
assay
may
employ
measur
inhibitori
activ
test
compound
enzym
determin
bind
affin
compound
target
protein
case
rel
high
puriti
target
protein
need
screen
system
present
recombin
sarscov
pro
obtain
high
puriti
express
escherichia
coli
mammalian
cell
accord
specif
substrat
activ
quench
fluoresc
reson
energi
transfer
fret
technolog
base
assay
high
perform
liquid
chromatographi
hplc
techniqu
enzymelink
immunosorb
assay
elisa
surfac
plasmon
reson
spr
techniqu
develop
potent
inhibitor
screen
sarscov
pro
fret
technolog
detect
proteolyt
activ
screen
inhibitor
fret
technolog
base
assay
usual
commonli
use
monitor
proteas
activ
identifi
inhibitor
effici
robust
ht
mode
assay
pair
fluorophor
fluoresc
donor
acceptor
quencher
attach
terminu
peptid
substrat
one
end
substrat
intact
excit
state
energi
donor
transfer
acceptor
fluoresc
quench
substrat
cleav
proteas
donor
acceptor
spatial
separ
subsequ
fluoresc
donor
detect
ensur
effici
intern
quench
commerci
avail
donorquench
pair
avail
far
mani
potenti
inhibitor
sarscov
pro
identifi
vitro
fretbas
assay
includ
symmetr
peptidomimet
compound
metalconjug
compound
thiophenecarboxyl
compound
bifunct
aryl
boron
acid
compound
quinolinecarboxyl
deriv
phthalhydrazidesubstitut
ketoglutamin
analogu
dipeptidomimet
bunsatur
ester
peptid
anilid
major
advantag
techniqu
sensit
speed
highthroughput
also
sever
disadvantag
firstli
fluorogen
substrat
rel
expens
special
substrat
prepar
secondli
sinc
absorpt
spectra
mani
synthet
natur
product
may
often
partli
overlay
emiss
spectra
fluorogen
donor
lem
nm
could
quench
fluoresc
thu
gener
fals
posit
moreov
trace
contamin
peptid
substrat
free
fluorogen
donor
eg
edan
would
result
high
fluoresc
background
hplc
techniqu
detect
proteolyt
activ
screen
inhibitor
hplc
techniqu
success
use
detect
proteolyt
activ
sarscov
pro
case
also
appli
inhibitor
screen
inhibitori
activ
compound
sarscov
pro
could
test
substrateanalog
peptid
cleavag
assay
assay
cleav
substrat
cleavag
product
could
separ
reversedphas
hplc
inhibitori
effici
test
compound
thu
calcul
compar
peak
area
cleav
substrat
product
control
substrat
without
proteas
chen
et
al
discov
sever
potent
sarscov
pro
inhibitor
screen
natur
product
librari
involv
compound
base
hplc
method
mani
compound
librari
chromogen
fretbas
assay
could
use
instead
hplc
techniqu
therebi
suitabl
test
chromogen
compound
howev
appli
screen
enorm
compound
highthroughput
format
timeconsum
separ
complic
experiment
process
rel
poor
sensit
elisa
techniqu
screen
inhibitor
elisa
repres
anoth
recent
develop
method
screen
inhibitor
sarscov
pro
cleavag
substrat
tvrlqagnat
gener
fusion
protein
ntermin
stag
ctermin
hsvtag
assay
system
substrat
fusion
protein
captur
antihsvtag
antibodi
well
incub
sarscov
pro
noncleavag
substrat
protein
detect
elisa
use
peroxidaseconjug
protein
abtsh
substrat
inhibitori
effici
test
compound
thu
evalu
accord
cleavag
activ
without
compound
techniqu
gener
sensit
previous
mention
method
wherea
reagent
use
expens
experiment
procedur
tediou
moreov
incomplet
wash
noncaptur
substrat
fusion
protein
lead
increas
fals
posit
besid
inhibitori
activ
determin
analysi
interact
compound
target
protein
also
key
part
drug
discoveri
process
method
screen
compound
receptor
bind
vitro
spr
biosensor
techniqu
provid
detail
inform
bind
affin
bind
kinet
techniqu
requir
immobil
target
protein
surfac
sensor
chip
monitor
bind
candid
compound
bind
compound
target
protein
caus
chang
refract
index
surfac
layer
sensor
chip
detect
chang
signal
optic
phenomenon
term
surfac
plasmon
reson
spr
date
mani
success
exampl
drug
screen
sprbase
assay
recent
report
discoveri
low
molecular
sarscov
pro
inhibitor
use
sprbase
biosensor
technolog
compar
techniqu
measur
molecular
interact
sprbase
assay
exhibit
sever
distinct
advantag
labelfre
sensit
realtim
noninvas
measur
low
sampl
consumpt
high
throughput
techniqu
could
help
rapid
select
follow
optim
lead
compound
base
detail
understand
compound
interact
target
protein
howev
case
immobil
target
protein
sensor
chip
might
affect
structur
conform
hit
obtain
sprbase
assay
probabl
nonspecif
bind
molecul
show
inhibitori
activ
solv
problem
posit
compound
must
use
corrobor
valid
target
protein
hit
test
enzymat
inhibitori
assay
spr
technolog
applic
primari
screen
ahead
enzymat
inhibitori
assay
addit
sever
new
vitro
techniqu
recent
report
literatur
exampl
immobil
metal
affin
chromatographi
imac
microarray
techniqu
appli
prepar
protein
microarray
recombin
histag
sarscov
pro
sarscov
pro
immobil
chip
could
thu
use
correspond
highthroughput
inhibitor
screen
coupl
method
detect
bind
affin
enzymat
inhibitori
activ
affin
capillari
electrophoresi
ace
anoth
report
method
develop
effect
simpl
way
largescal
drug
screen
evalu
method
mainli
determin
bind
constant
test
compound
evalu
chang
migrat
time
inhibitor
differ
concentr
sarscov
pro
principl
two
method
drug
discoveri
techniqu
high
effici
short
analysi
time
eas
autom
indepth
inhibitor
investig
carri
furthermor
isotherm
titrat
calorimetri
itc
technolog
afford
promis
platform
studi
inhibitorprotein
interact
determin
bind
affin
stoichiometri
thermodynam
paramet
singl
inject
experi
howev
method
unsuit
largescal
inhibitor
screen
due
rel
high
sampl
consumpt
long
experiment
durat
compound
identifi
potenti
inhibitor
target
protein
vitro
necessari
establish
relev
cellular
physiolog
system
test
inhibitori
efficaci
vivo
cellbas
assay
system
thoroughli
review
signific
advantag
vitro
assay
compar
vitro
screen
method
cellbas
assay
requir
purif
target
protein
close
normal
physiolog
situat
moreov
cellbas
assay
provid
valuabl
insight
bioavail
cytotox
test
compound
howev
must
realiz
experiment
period
cellbas
assay
rel
longer
vitro
assay
discoveri
antisar
agent
popular
method
cellbas
assay
directli
test
antivir
activ
compound
sever
group
report
use
mammalian
cell
antisar
inhibitor
screen
vero
cell
cell
line
hypodiploid
chromosom
count
initi
kidney
normal
adult
african
green
monkey
extens
use
detect
viru
infect
incub
differ
concentr
test
compound
infect
sarscov
degre
protect
offer
test
compound
sarscov
infect
measur
vero
cell
cytopath
effect
plaqu
reduct
assay
viru
rna
concentr
supernat
cytotox
compound
could
determin
mtt
bromid
mt
tetrazolium
salt
assay
moreov
western
blot
analysi
antispik
protein
monoclon
polyclon
antibodi
immunofluoresc
assay
ifa
flow
cytometri
assay
elisa
techniqu
appli
character
action
mechan
activ
compound
cellbas
ciscleavag
assay
anoth
cellbas
method
directli
test
inhibitori
efficaci
compound
sarscov
pro
vivo
report
gene
sarscov
pro
specif
substrat
sequenc
luciferas
gene
coconstruct
vector
subsequ
transfect
vero
cell
stabl
cell
line
express
pro
sluc
fusion
protein
select
sinc
sarscov
pro
kda
fuse
nterminu
luciferas
result
dramat
decreas
luciferas
activ
increas
luciferas
activ
could
consid
repres
vivo
ciscleavag
activ
sarscov
pro
inhibitori
activ
calcul
measur
luciferas
activ
presenc
test
compound
vari
concentr
consid
fact
sometim
inhibitori
activ
sarscov
pro
might
show
poor
correl
effect
antivir
activ
cellbas
assay
directli
detect
antivir
activ
compound
superior
cellbas
ciscleavag
assay
sinc
outbreak
sar
great
effort
devot
antisar
treatment
past
year
gain
valuabl
knowledg
sarscov
includ
phylogenet
properti
genom
organ
well
structur
function
charact
major
protein
involv
viral
life
cycl
although
diseas
control
convent
measur
rapid
detect
infect
control
isol
quarantin
efficaci
therapi
drug
sar
avail
date
review
give
brief
summari
exist
emerg
technolog
appli
discoveri
antisar
agent
tabl
mainli
two
feasibl
strategi
therapeut
compound
identif
sar
diseas
one
targetbas
drug
discoveri
vitro
biochem
assay
exampl
screen
inhibitor
inhibit
activ
bind
substratebind
pocket
sarscov
encod
enzym
exampl
pro
report
inhibitor
discoveri
studi
adopt
pattern
cellbas
assay
measur
antiviru
effect
compound
firstli
determin
possibl
target
protein
activ
compound
targetbas
drug
discoveri
timesav
conveni
compar
latter
method
must
process
biosafeti
level
laboratori
screen
throughput
rel
low
despit
experiment
screen
alway
slow
labori
procedur
howev
virtual
screen
approach
base
structur
sarscov
encod
major
protein
reliabl
narrow
number
potenti
candid
wwwdrugdiscoverytodaycom
experiment
test
finish
virtual
screen
set
kind
filter
hit
obtain
purchas
synthesi
use
enzymat
cellbas
inhibitori
activ
determin
time
structur
optim
lead
compound
quantif
structureact
relationship
may
consid
drug
discoveri
strategi
structur
alter
biolog
evalu
therefor
virtual
screen
good
choic
begin
discoveri
inhibitor
ahead
targetbas
cellbas
assay
vitro
biochem
assay
spr
technolog
determin
bind
test
compound
target
protein
method
could
appli
enzymat
inhibitori
assay
thu
reduc
screen
scale
follow
enzymat
inhibitori
assay
fret
method
practic
identifi
potent
inhibitor
effici
robust
ht
mode
limit
chromogen
compound
hplc
method
make
weak
therefor
two
complementari
techniqu
may
integr
effect
discoveri
inhibitor
sarscov
time
elisa
ace
techniqu
may
also
provid
use
inform
bind
affin
inhibitori
activ
test
compound
addit
cellbas
assay
assess
antivir
activ
compound
biolog
system
close
physiolog
environ
allow
earlier
indic
potenti
compound
toxic
offer
attract
altern
vitro
biochem
assay
develop
modern
combinatori
chemistri
ht
approach
drug
discoveri
process
much
acceler
integr
differ
complementari
techniqu
may
optim
drug
discoveri
strategi
success
identif
extens
antisar
inhibitor
proven
interdisciplinari
paradigm
discoveri
therapeut
compound
combin
differ
techniqu
similar
approach
could
appli
discoveri
therapeut
virus
highli
pathogen
avian
influenza
viru
